Outcome of patients receiving photodynamic therapy for early esophageal cancer

Luigi Corti, John Skarlatos, Caterina Boso, Fabrizio Cardin, Lambrini Kosma, Michael I. Koukourakis, Alexandra Giatromanolaki, Lorenzo Norberto, Moshe Shaffer, Kostantinos Beroukas

Research output: Contribution to journalArticle

Abstract

Purpose: Photodynamic therapy (PDT) has shown remarkable activity in a variety of human cancers. In the present study, we report the effects of PDT on inoperable early-stage esophageal cancer. Methods and Materials: Sixty-two patients were treated with an argon dye laser (630 nm wavelength, 300-800 mW of power, energy dose of 200-300 J/cm) after intravenous injection of 5 mg/kg of hematoporphyrin derivative. Eighteen patients (29.5%) had in situ carcinoma (Tis), 30 (48.5%) had T1-stage cancer, 7 (11%) had T2-stage cancer, and 7 (11%) had recurrent disease in the anastomotic area after previous surgery without evidence of invasion outside the lumen. Patients with residual disease after two rounds of PDT received definitive radiotherapy. Patients were evaluated for response to therapy and survival. The follow-up time ranged from 3 to 90 months (median, 32 months). Results: The complete response (CR) rate was 37% (23 of 62) in patients who received PDT alone and 82% (51 of 62) in those who also received radiotherapy. The CR rate after PDT alone was statistically higher (p = 0.04) for patients who had Tis/T1 lesions (21 of 48; 44%) than for those with T2-stage disease (2 of 7; 28%) or recurrent tumors (0 of 7; 0%). Fifty-two percent of patients who had CR following PDT alone did not suffer local tumor recurrence. The median local progression-free survival times after PDT and additional radiotherapy (in cases with incomplete response) was 49 months for Tis- and T1-stage lesions, 30 months for those with T2-stage disease, and 14 months for patients with locally recurrent disease. Patients who completely responded to PDT had a median overall survival (OS) of 50 months, which was significantly longer (p <0.003) than that of patients not responding to PDT. Toxicity was minimal; we recorded three cases of esophageal stenosis (7%) and one case of tracheo- esophageal fistula (2.5%) after combined PDT and radiotherapy. Conclusion: PDT is an effective regimen for early esophageal cancer, giving a CR rate of about 40%, long-term local control and favorable overall survival. Additional radiotherapy in cases of incomplete response to PDT is effective and potentially curative in another 45% of cases. (C) 2000 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)419-424
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume47
Issue number2
DOIs
Publication statusPublished - May 1 2000

Fingerprint

Photochemotherapy
Esophageal Neoplasms
therapy
cancer
Radiotherapy
radiation therapy
Neoplasms
Survival
lesions
Hematoporphyrin Derivative
tumors
Tracheoesophageal Fistula
Dye Lasers
Esophageal Stenosis
argon lasers
Argon
Carcinoma in Situ
lumens
Intravenous Injections
Disease-Free Survival

Keywords

  • Esophageal cancer
  • Hematoporphyrin derivative
  • Photodynamic therapy
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Outcome of patients receiving photodynamic therapy for early esophageal cancer. / Corti, Luigi; Skarlatos, John; Boso, Caterina; Cardin, Fabrizio; Kosma, Lambrini; Koukourakis, Michael I.; Giatromanolaki, Alexandra; Norberto, Lorenzo; Shaffer, Moshe; Beroukas, Kostantinos.

In: International Journal of Radiation Oncology Biology Physics, Vol. 47, No. 2, 01.05.2000, p. 419-424.

Research output: Contribution to journalArticle

Corti, L, Skarlatos, J, Boso, C, Cardin, F, Kosma, L, Koukourakis, MI, Giatromanolaki, A, Norberto, L, Shaffer, M & Beroukas, K 2000, 'Outcome of patients receiving photodynamic therapy for early esophageal cancer', International Journal of Radiation Oncology Biology Physics, vol. 47, no. 2, pp. 419-424. https://doi.org/10.1016/S0360-3016(00)00450-8
Corti, Luigi ; Skarlatos, John ; Boso, Caterina ; Cardin, Fabrizio ; Kosma, Lambrini ; Koukourakis, Michael I. ; Giatromanolaki, Alexandra ; Norberto, Lorenzo ; Shaffer, Moshe ; Beroukas, Kostantinos. / Outcome of patients receiving photodynamic therapy for early esophageal cancer. In: International Journal of Radiation Oncology Biology Physics. 2000 ; Vol. 47, No. 2. pp. 419-424.
@article{cd153b3326364904b141481c7fea6b14,
title = "Outcome of patients receiving photodynamic therapy for early esophageal cancer",
abstract = "Purpose: Photodynamic therapy (PDT) has shown remarkable activity in a variety of human cancers. In the present study, we report the effects of PDT on inoperable early-stage esophageal cancer. Methods and Materials: Sixty-two patients were treated with an argon dye laser (630 nm wavelength, 300-800 mW of power, energy dose of 200-300 J/cm) after intravenous injection of 5 mg/kg of hematoporphyrin derivative. Eighteen patients (29.5{\%}) had in situ carcinoma (Tis), 30 (48.5{\%}) had T1-stage cancer, 7 (11{\%}) had T2-stage cancer, and 7 (11{\%}) had recurrent disease in the anastomotic area after previous surgery without evidence of invasion outside the lumen. Patients with residual disease after two rounds of PDT received definitive radiotherapy. Patients were evaluated for response to therapy and survival. The follow-up time ranged from 3 to 90 months (median, 32 months). Results: The complete response (CR) rate was 37{\%} (23 of 62) in patients who received PDT alone and 82{\%} (51 of 62) in those who also received radiotherapy. The CR rate after PDT alone was statistically higher (p = 0.04) for patients who had Tis/T1 lesions (21 of 48; 44{\%}) than for those with T2-stage disease (2 of 7; 28{\%}) or recurrent tumors (0 of 7; 0{\%}). Fifty-two percent of patients who had CR following PDT alone did not suffer local tumor recurrence. The median local progression-free survival times after PDT and additional radiotherapy (in cases with incomplete response) was 49 months for Tis- and T1-stage lesions, 30 months for those with T2-stage disease, and 14 months for patients with locally recurrent disease. Patients who completely responded to PDT had a median overall survival (OS) of 50 months, which was significantly longer (p <0.003) than that of patients not responding to PDT. Toxicity was minimal; we recorded three cases of esophageal stenosis (7{\%}) and one case of tracheo- esophageal fistula (2.5{\%}) after combined PDT and radiotherapy. Conclusion: PDT is an effective regimen for early esophageal cancer, giving a CR rate of about 40{\%}, long-term local control and favorable overall survival. Additional radiotherapy in cases of incomplete response to PDT is effective and potentially curative in another 45{\%} of cases. (C) 2000 Elsevier Science Inc.",
keywords = "Esophageal cancer, Hematoporphyrin derivative, Photodynamic therapy, Radiotherapy",
author = "Luigi Corti and John Skarlatos and Caterina Boso and Fabrizio Cardin and Lambrini Kosma and Koukourakis, {Michael I.} and Alexandra Giatromanolaki and Lorenzo Norberto and Moshe Shaffer and Kostantinos Beroukas",
year = "2000",
month = "5",
day = "1",
doi = "10.1016/S0360-3016(00)00450-8",
language = "English",
volume = "47",
pages = "419--424",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Outcome of patients receiving photodynamic therapy for early esophageal cancer

AU - Corti, Luigi

AU - Skarlatos, John

AU - Boso, Caterina

AU - Cardin, Fabrizio

AU - Kosma, Lambrini

AU - Koukourakis, Michael I.

AU - Giatromanolaki, Alexandra

AU - Norberto, Lorenzo

AU - Shaffer, Moshe

AU - Beroukas, Kostantinos

PY - 2000/5/1

Y1 - 2000/5/1

N2 - Purpose: Photodynamic therapy (PDT) has shown remarkable activity in a variety of human cancers. In the present study, we report the effects of PDT on inoperable early-stage esophageal cancer. Methods and Materials: Sixty-two patients were treated with an argon dye laser (630 nm wavelength, 300-800 mW of power, energy dose of 200-300 J/cm) after intravenous injection of 5 mg/kg of hematoporphyrin derivative. Eighteen patients (29.5%) had in situ carcinoma (Tis), 30 (48.5%) had T1-stage cancer, 7 (11%) had T2-stage cancer, and 7 (11%) had recurrent disease in the anastomotic area after previous surgery without evidence of invasion outside the lumen. Patients with residual disease after two rounds of PDT received definitive radiotherapy. Patients were evaluated for response to therapy and survival. The follow-up time ranged from 3 to 90 months (median, 32 months). Results: The complete response (CR) rate was 37% (23 of 62) in patients who received PDT alone and 82% (51 of 62) in those who also received radiotherapy. The CR rate after PDT alone was statistically higher (p = 0.04) for patients who had Tis/T1 lesions (21 of 48; 44%) than for those with T2-stage disease (2 of 7; 28%) or recurrent tumors (0 of 7; 0%). Fifty-two percent of patients who had CR following PDT alone did not suffer local tumor recurrence. The median local progression-free survival times after PDT and additional radiotherapy (in cases with incomplete response) was 49 months for Tis- and T1-stage lesions, 30 months for those with T2-stage disease, and 14 months for patients with locally recurrent disease. Patients who completely responded to PDT had a median overall survival (OS) of 50 months, which was significantly longer (p <0.003) than that of patients not responding to PDT. Toxicity was minimal; we recorded three cases of esophageal stenosis (7%) and one case of tracheo- esophageal fistula (2.5%) after combined PDT and radiotherapy. Conclusion: PDT is an effective regimen for early esophageal cancer, giving a CR rate of about 40%, long-term local control and favorable overall survival. Additional radiotherapy in cases of incomplete response to PDT is effective and potentially curative in another 45% of cases. (C) 2000 Elsevier Science Inc.

AB - Purpose: Photodynamic therapy (PDT) has shown remarkable activity in a variety of human cancers. In the present study, we report the effects of PDT on inoperable early-stage esophageal cancer. Methods and Materials: Sixty-two patients were treated with an argon dye laser (630 nm wavelength, 300-800 mW of power, energy dose of 200-300 J/cm) after intravenous injection of 5 mg/kg of hematoporphyrin derivative. Eighteen patients (29.5%) had in situ carcinoma (Tis), 30 (48.5%) had T1-stage cancer, 7 (11%) had T2-stage cancer, and 7 (11%) had recurrent disease in the anastomotic area after previous surgery without evidence of invasion outside the lumen. Patients with residual disease after two rounds of PDT received definitive radiotherapy. Patients were evaluated for response to therapy and survival. The follow-up time ranged from 3 to 90 months (median, 32 months). Results: The complete response (CR) rate was 37% (23 of 62) in patients who received PDT alone and 82% (51 of 62) in those who also received radiotherapy. The CR rate after PDT alone was statistically higher (p = 0.04) for patients who had Tis/T1 lesions (21 of 48; 44%) than for those with T2-stage disease (2 of 7; 28%) or recurrent tumors (0 of 7; 0%). Fifty-two percent of patients who had CR following PDT alone did not suffer local tumor recurrence. The median local progression-free survival times after PDT and additional radiotherapy (in cases with incomplete response) was 49 months for Tis- and T1-stage lesions, 30 months for those with T2-stage disease, and 14 months for patients with locally recurrent disease. Patients who completely responded to PDT had a median overall survival (OS) of 50 months, which was significantly longer (p <0.003) than that of patients not responding to PDT. Toxicity was minimal; we recorded three cases of esophageal stenosis (7%) and one case of tracheo- esophageal fistula (2.5%) after combined PDT and radiotherapy. Conclusion: PDT is an effective regimen for early esophageal cancer, giving a CR rate of about 40%, long-term local control and favorable overall survival. Additional radiotherapy in cases of incomplete response to PDT is effective and potentially curative in another 45% of cases. (C) 2000 Elsevier Science Inc.

KW - Esophageal cancer

KW - Hematoporphyrin derivative

KW - Photodynamic therapy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034193167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034193167&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(00)00450-8

DO - 10.1016/S0360-3016(00)00450-8

M3 - Article

C2 - 10802369

AN - SCOPUS:0034193167

VL - 47

SP - 419

EP - 424

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -